CRVS - Corvus Pharmaceuticals Inc
IEX Last Trade
4.48
0.340 7.589%
Share volume: 794,291
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$4.14
0.34
8.21%
Fundamental analysis
21%
Profitability
25%
Dept financing
4%
Liquidity
48%
Performance
15%
Performance
5 Days
4.19%
1 Month
69.70%
3 Months
112.32%
6 Months
94.78%
1 Year
93.94%
2 Year
365.60%
Key data
Stock price
$4.48
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.05 - $4.75
52 WEEK CHANGE
$1.10
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Richard Miller
Region: US
Website: http://www.corvuspharma.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.corvuspharma.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Recent news